Updated

Foreign pharmaceutical companies supplying cancer drugs to Russia spend about $500 million a year on bonuses for intermediaries, suppliers and hospital staff, according to an investigation by the Russian outlet Proekt, reported by Meduza. The findings rest on testimony from a senior executive at an international drugmaker operating in Russia. The sources give no response from the companies or Russian authorities.